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Abstract Oncolytic virotherapy is an experimental cancer treatment that
uses genetically engineered viruses to target and kill cancer cells. One ma-
jor limitation of this treatment is that virus particles are rapidly cleared by
the immune system, preventing them from arriving at the tumour site. To
improve virus survival and infectivity Kim et al (2011) modified virus parti-
cles with the polymer polyethylene glycol (PEG) and the monoclonal antibody
herceptin. While PEG modification appeared to improve plasma retention and
initial infectivity it also increased the virus particle arrival time. We derive a
mathematical model that describes the interaction between tumour cells and
an oncolytic virus. We tune our model to represent the experimental data by
Kim et al (2011) and obtain optimised parameters. Our model provides a plat-
form from which predictions may be made about the response of cancer growth
to other treatment protocols beyond those in the experiments. Through model
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simulations we find that the treatment protocol affects the outcome dramati-
cally. We quantify the effects of dosage strategy as a function of tumour cell
replication and tumour carrying capacity on the outcome of oncolytic virother-
apy as a treatment. The relative significance of the modification of the virus
and the crucial role it plays in optimising treatment efficacy is explored.
Keywords Oncolytic virus ¨ Optimisation ¨ Mathematical modelling ¨
Ordinary differential equations
1 Introduction
The use of viruses as a cancer treatment has been investigated since the start
of the nineteenth century (Kelly and Russell (2007)). Oncolytic virotherapy is
a field exploring the use of genetically engineered viruses to specifically target
and kill cancer cells and is currently achieving a lot of success in clinical tri-
als, for example see Aghi and Martuza (2005); Jebar et al (2015); Wang et al
(2016).
An oncolytic virus is a genetically engineered wild type virus that expresses
specific genes allowing it to selectively lyse cancerous cells. Lysis is the process
by which a virus infects a cell and creates thousands of replicates of itself caus-
ing the cell to rupture. In this process, the cell dies and the new virus particles
are released to infect nearby cells. A major problem with oncolytic virotherapy
is the short retention time of the virus in the blood due to immune clearance
(Kim et al (2011)). To combat this Kim et al (2011) modified an oncolytic
adenovirus with the non-immunogenic polymer polyethylene glycol (PEG).
PEG modification is known to increase the survival time of virus particles as
they travel through the blood stream by shielding them from immune detec-
tion (Mok et al (2005)). Modifying an oncolytic virus with a non-immunogenic
polymer provides it with a higher chance of initially reaching the tumour cells
before being cleared (Mok et al (2005)). The disadvantage of PEG modifica-
tion is that it weakens the ability of the virus to interact with and target
tumour cells, which is believed to inhibit virus infectivity (Kim et al (2011)).
For some cancer types, the decrease in efficacy incurred through PEG mod-
ification can be ameliorated by conjugating the viruses with herceptin. Her-
ceptin is a Her2/neu-specific monoclonal antibody that is used regularly in
cancer treatment as it recognises and binds to Her2, found over-expressed on
the surface of 20-30% of breast cancer cells (Slamon et al (1987)). The con-
jugation of an oncolytic adenovirus with herceptin allows the modified virus
to selectively accumulate within tumours expressing Her2, leading to a higher
probability of tumour cell infection and in turn tumour cell death.
In this article we derive a system of ordinary differential equations (ODEs)
to model the interaction between oncolytic viruses and tumour cells. Using the
experiments of Kim et al (2011) conducted with adenovirus with and without
PEG modification and herceptin conjugation, we are able to optimise the pa-
rameters of the model. We show that the system of ODEs derived embodies
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all the major processes acting and is sufficient to replicate the experimen-
tal results. We then use the model to investigate the effects of the treatment
protocol on tumours of different virulence and magnitude.
2 Method
2.1 Experimental data
Kim et al (2011) conducted an in vivo experiment monitoring the change in
tumour volume under four different treatment protocols. One control treat-
ment and three varying oncolytic adenoviruses were intravenously injected
into six nude mice1 with pre-established tumours of size 100-120mm3. The con-
trol treatment was an injection of 100µL of phosphate buffered saline (PBS),
and the three virus based injections were; an oncolytic adenovirus without
any modification (Ad), a PEG-modified adenovirus (Ad-PEG) and a PEG-
modified adenovirus conjugated with herceptin (Ad-PEG-HER). In all virus
experiments 1ˆ1010 viral particles were injected intravenously on each of days
0, 2 and 4. The tumour volume in each mouse was recorded every second
day for 60 days from the first injection. The length and width of the tumour
was measured using a calliper and the tumour volume was estimated as 0.523
ˆ lengthˆwidth2. Here the tumour volume is assumed to be proportional to
the number of tumour cells, and we assume the density to be 106cells/mm3
(Wares et al (2015)).
2.2 Model development
Our motivation in modelling this system is to accurately reflect the dynamics
of a tumour-viral treatment. As the experiments were conducted on nude mice,
we considered the immune responses to be negligible. We have used mass ac-
tion in our model as a mean-field approximation of the geometric and spatial
effects of the virus-tumour interaction, with these effects incorporated within
the rate constants. It can be seen from the results below that our model can
replicate the observed experimental results under this assumption.
There are three state variables considered in the model, and their interac-
tions, Fig. 1, are modelled using a system of ODEs:
dV
dt
“ uV ptq ´ dV V ` αdII, (1)
dS
dt
“ r log
ˆ
L
S
˙
S ´
βSV
T
, (2)
dI
dt
“
βSV
T
´ dII, (3)
uV ptq “ V0pδptq ` δpt´ 2q ` δpt´ 4qq, (4)
1 Nude mice have non-functioning immune systems.
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Fig. 1: Compartmental diagram of the interactions between an intravenously injected on-
colytic virus, V , and a population of tumour cells, S and I, the susceptible and infected
tumour cells respectively, see Eqs. (1)-(4).
where t is time, V is the density of virus particles at the tumour site, S is the
density of susceptible tumour cells, I is the density of infected tumour cells
and T is the total tumour cell population.
Mirroring the experiments by Kim et al., an amount, V0, of virus is injected
intravenously on days 0, 2 and 4, Eq. 4, where δ is the delta function. The
virus decays at a rate dV . In addition, infected tumour cells undergo lysis at
rate dI , with each lysed cell generating α new virus particles.
Any virus produced via replication within the tumour cells does not have
PEG modification nor conjugation with herceptin. In this study we assign a
single average infectivity, β (which also accounts for tumour cell discovery by
the virus) and a single decay rate, dV , for the combined populations of original
and replicated viruses.
To model tumour growth we have assumed that the susceptible population
S are the only population of tumour cells undergoing proliferation. The growth
is described by the Gompertz growth function, r log
`
L
S
˘
S, where L is the
carrying capacity of the tumour and r is the proliferation constant (see for
instance Laird (1964)). Viruses at the tumour site infect susceptible tumour
cells as βSV
T
and, as stated earlier, infected cells die through lysis at a rate dI .
2.3 Parameter fitting and model simulation
To obtain parameter estimates for the model we performed both individual
and simultaneous optimisations to the experimental data of Kim et al (2011)
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Table 1: Common and experiment specific model parameters. In the optimi-
sation of the model certain parameters were assumed to be common to all
experiments.
Experiment
Parameter PBS Ad Ad-PEG Ad-PEG-HER
Tumour growth rate r
Tumour carrying capacity L
Tumour cell burst rate - dI
Viral decay rate - dV
Initial tumour size S0 PBS S0 Ad S0 Ad´PEG S0 Ad´PEG´HER
Infection rate - β Ad β Ad´PEG β Ad´PEG´HER
detailed in Section 2.1. Firstly, the model was optimised using the time-series
data for each individual mouse to obtain independent estimates of both the
common parameters and those specific to that experiment, Table 1. Initially
the V and I populations were zero. In the case of the PBS (control) experiment,
as there were no viral particles in the PBS injection, V0 “ 0, and therefore
there were no infected cells. For the viral experiments, V0 “ 10
10 particles.
To reduce the degrees of freedom, the number of new virus particles created
through lysis (viral burst size) was fixed α “ 3500 as reported in Chen et al
(2001).
To quantify the average response to the treatment protocol we optimised
the model parameters (Table 1) using all the experimental data simultane-
ously. The tumour growth dynamics, parameters r and L, were considered to
be common across all experiments. Similarly the parameters relating to viral
burst rate dI and viral decay dV were considered to be common to all viral
experiments. The infectivity and initial tumour size were taken to be protocol
specific. We hypothesised that the different levels of modification in the virus
would result in different infectivity rates, therefore this value must be free to
vary between experiments. Overall 11 parameter values were optimised using
750 data points across the four data sets.
The simulations and optimisations were undertaken using Matlab (R2016b,
Mathworks 2016). We used non-linear least squares (lsqnonlin) via the trust-
region-reflective algorithm to fit our models to data. The termination toler-
ance, which is the minimum change in the objective function, was 1 ˆ 10´6.
The maximum number of function evaluations was fixed as 100ˆN , the num-
ber of parameters, and the maximum number of iterations for the fit was 400.
The solver ode45 was used for each iteration of the fitting algorithm and to
simulate the model.
The confidence intervals for the parameters were calculated using the in-
built nlparci function which used the Jacobian from lqnonlin in conjunction
with optimised parameter values and corresponding residual. The simultane-
ous fit equally weighted each of the experimental data sets, accounting for the
difference in the number of data time points between sets.
When solving Eqs. (1)-(3) numerically the variable T was replaced by T `ǫ
for ǫ ą 0, small, to avoid the singularity occurring as T Ñ 0.
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3 Results
3.1 Model optimisation
Using the tumour time-series results of Kim et al (2011) detailed in Section 2.1
the model parameters were optimised as described in Section 2.3. Firstly, the
individual time course data for each experiment was used to estimate the pa-
rameters of the model associated with each protocol. Fig. 2 shows the tumour
cell population as a function of time for each experiment overlaid with the
individually optimised models.
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Fig. 2: Tumour cell population as a function of time for (a) PBS (Control),
(b) Ad, (c) Ad-PEG and (d) Ad-PEG-HER treatment protocols. The data for
each mouse is shown with joined circles and the optimised model output for
each individual case is shown overlaid as a thicker line of the same colour.
Note I “ 0 for the control case.
The four data sets (PBS, Ad, Ad-PEG and Ad-PEG-HER) were then used
simultaneously to optimise the model parameters. The model output for the
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Fig. 3: Tumour cell population as a function of time for (a) Control, (b) Ad, (c)
Ad-PEG and (d) Ad-PEG-HER treatment protocols. The experimental data is
plotted as circles (grey), and the output of the model optimised simultaneously
to all data points for all mice under each protocol is shown as a solid line. The
mean of the experimental data is shown as a dashed line. Note I “ 0 for the
control case.
simultaneously optimised system is shown overlaid with the experimental data
in Fig. 3. The parameter values and fit characteristics of the simultaneous op-
timisation are shown in Table 2. The parameter values obtained from both the
individual and the simultaneous optimisations are shown in Fig. 4. It can be
seen that the simultaneous fit parameter values generally lay within the dis-
tribution of the parameter estimates obtained in the individual optimisations.
For some experiment-specific parameters the simultaneous parameter esti-
mates were dissimilar to those from the individual optimisations, Fig. 4. These
experiment-specific parameters were constrained by fewer data points, and al-
though each data set was weighted equally, the constraints on the common
parameters resulted in different optimal values.
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Fig. 4: Parameter estimates from the individual and simultaneous optimisa-
tion to all data. The small (grey) circles correspond to the estimates of the
parameters from each mouse individually. The large open circles correspond
to the simultaneous optimisation parameter estimates. The infectivity of the
virus, β, and the initial tumour size, S0, were experiment specific. The central
white line is the mean of the data, the blue box indicates the 95% confidence
interval and the green box indicates one standard deviation from the mean.
Note that there were fewer data points constraining the experiment-specific
parameters.
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Table 2: Parameter values and fit statistics for the simultaneous optimisation
of the model with all data.
Parameter Description PBS Ad Ad-PEG Ad-PEG-HER 95% Conf. Int.
α (fixed) viral burst size - 3500 3500 3500 -
L carrying capacity 3490 3490 3490 3490 (2230, 4750)
r (day´1) growth rate 0.037 0.037 0.037 0.037 (0.018, 0.056)
dI (day
´1) burst rate - 0.1 0.1 0.1 (-2, 2)
dV (day
´1) viral decay rate - 1.38 1.38 1.38 (-52, 55)
S0 PBS initial tumour size 251 - - - (139, 453)
S0 Ad initial tumour size - 200 - - (63, 337)
S0 Ad´PEG initial tumour size - - 223 - (69, 378)
S0 Ad´PEG´HER initial tumour size - - - 153 (37, 269)
β Ad (day
´1) infection rate - 0.562 - - (16, 17)
β Ad´PEG (day
´1) infection rate - - 0.771 - (-19, 21)
β Ad´PEG´HER (day
´1) infection rate - - - 0.862 (-20, 22)
Goodness of fit statistics Value
R-squared 0.4286
Pearson’s r correlation coefficient 0.6547
3.2 Simulating heterogeneity in tumours and viral infectivity
Analysis of the sensitivity of the model to perturbations in tumour and virus
characteristics was carried out by simulating the Ad-PEG-HER model with
the simultaneously optimised parameter values, Table. 2, and the experiment
application profile, Eq. 4. To determine if the outcome of treatment was de-
pendent on the tumour characteristics the tumour population as a function
of time was simulated, with separate perturbations to the growth rate r and
initial tumour size S0, keeping the other parameters constant, see Fig. 5a and
5b.
Perturbations in viral characteristics are also thought to alter the treatment
outcome. Increasing virulence of the virus, for example in its infectivity, has
been hypothesised to lead to a more successful treatment. The effect of changes
in the viral infectivity on the tumour cell population is shown in Fig. 5c.
3.3 Simulating the effects of different treatment applications: changing the
viral application profile, uV ptq.
Investigations of the sensitivity of the model to alterations in the application
profile uV ptq were carried out by simulating the simultaneously optimised Ad-
PEG-HER model, Table 2. The application profile uV ptq determines the total
amount of virus and the pattern by which it is delivered. Different injection
profiles were considered,
uV ptq “
D0
n
nÿ
i“1
δpt´ pi ´ 1qξq (5)
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Fig. 5: Tumour cell population as a function of time predicted by the simul-
taneously optimised model for various (a) growth rates r between 0.001 and
0.3 (day´1), (b) initial tumour populations S0 between 1 and 300 (cells ˆ10
6)
and (c) infectivity rates β between 0.4 and 4.5 (day´1). The colormap bar
matches the corresponding parameter value. All other parameters for each set
were given by Table 2 common and Ad-PEG-HER experiment specific values.
The dashed line represents the model solutions for unperturbed Ad-PEG-HER
parameters in Table 2. Note the plots have different vertical scales.
where n is the number of injections, D0 is the total amount injected, ξ is the
number of days between injections and δ is the delta function.
We simulated the effect on the tumour cell population from day 0 to 100
under different total dosages and application profiles uV ptq. The model was
simulated using the parameters simultaneously optimised for the Ad-PEG-
HER virus, Table 2, with the dose, D0, between 0 and 1500, the number of
injections, n, between 0 and 6 and the period between injections, ξ, between
0 and 10 days.
One major concern in viral treatments is the toxicity caused through the
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accumulation of the virus in the system. To examine this we determined the
maximum virus level reached at any time between day 0 to 60 for each appli-
cation profile, Fig. 6a.
To quantify the effects of differing application profiles on treatment out-
come we measured the changes in eradication half time. We define the eradi-
cation half time as the time taken for the tumour to decrease to and remain
smaller than half its initial size. The minimum viral dose required for a finite
eradication half time was determined for each application profile, Fig. 6b.
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Fig. 6: Effect of treatment profile. (a) Maximum viral population as a function
of the total viral dose, D0, for each application profile with inset detail at low
doses. (b) Eradication half time as a function of the minimum total viral
dose D0 required. Seven different application protocols were simulated for the
simultaneous optimised model for Ad-PEG-HER, Table 2 for the indicated
number of injections, n, and days between injections, ξ.
4 Discussion
Oncolytic virotherapy is fast becoming a prominent cancer treatment; how-
ever, there is still a long way to go before a curative treatment will exist.
The simple mathematical model we have derived describes the interaction be-
tween an oncolytic virus and tumour cells. The model identifies the primary
processes operating, replicating and embodying observed experimental results
from Kim et al (2011), Figs 2 and 3. When fit to the data for individual cases
it can be seen that the model easily replicates a wide range of treatment re-
sponses. The ability of the model to replicate the data accurately is reaffirmed
by the R-squared and Pearson’s r Correlation coefficient Table 2. From this
we can conclude that our model is a reliable and malleable representation for
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the interaction between an oncolytic virus and tumour cells.
If we examine specifically the parameter values in Table 2 obtained through
the simultaneous fitting of the model to the tumour time-series data, we can
see that increasing viral modification, Ad to Ad-PEG to Ad-PEG-HER, in-
creased the infectivity of the treatments with Ad-PEG-HER having the highest
infectivity rate.
In comparing the parameter estimates from the individual and simultane-
ous optimisations in Fig. 4 we can quantify the effects of more data points on
the accuracy of the parameter values. Some parameters are less constrained
and by constraining the other parameters more heavily with more data the
search space for these experiment-specific parameters is further restricted. For
the parameter dI , the lysis rate of the infected tumour cells, we see evidence of
a bimodal distribution from the individual optimisations; however, restricting
this parameter to be common across all data sets in the simultaneous optimi-
sation constrains the search space and determines which mode best represents
the mean response under all experimental protocols.
Surface modification of an oncolytic virus, for example PEG-modification
and herceptin conjugation, poses a problem in treatment optimisation. Any
virus produced via replication within a tumour cell will lose surface modifica-
tion after one replication. Whilst we did not explicitly model this transforma-
tion in the current model it can be seen that the model is still able to embody
the experimental observations.
It is widely known that humans are incredibly heterogeneous and as such,
individual responses to treatment will vary. The analysis in Section 3.2 shows
there is a strong relationship between a successful treatment outcome and the
aggressive nature of the tumour. Using the model as a platform for prediction,
we see that the treatment efficacy is highly dependent upon the initial tumour
size and proliferation rate, Fig. 5a and 5b. Simulations of the treatment proto-
col on tumours of differing characteristics shows that the treatment is capable
of slowing and possibly reversing tumour growth. The tumour cell population
in the presence of viral treatment is highly sensitive to the intrinsic tumour cell
growth rate, r, Fig. 5a. The results suggest that the slower the tumour cells are
proliferating the more likely the viral treatment can reduce the tumour to a
manageable size. However, for aggressive tumours with high growth rates r, we
see an initial plateauing of the tumour cell population showing the viral treat-
ment taking effect, however this is followed by an increase in tumour size. This
suggests that the overall tumour proliferation is eventually too high for the
viral lysis to overcome and we see an increase in tumour cell population with
time. If the infectivity of the virus were higher then the outcome would most
likely be similar to that of less aggressively growing tumours. Interestingly, it
would appear that the treatments are more effective in halting tumour pro-
gression when the initial tumour size, S0, is mid-range, around 50ˆ10
6 cells
(or 50 mm3), Fig. 5b. It may be that smaller tumours are initially hidden
from the treatment, delaying the treatment effect. The maximum tumour cell
population was reduced as S0 reduced and the peak tumour population time
delayed. However, for extremely small S0, the tumour appears to escape the
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treatment, with the peak tumour cell population again increasing as S0 de-
creases. From both Fig. 5a and 5b, we can conclude that heterogeneity in the
tumour characteristics will alter treatment outcome substantially and we need
to be thorough in our investigations of this phenomenon moving forward in
this field.
Our motivation in deriving our model was not only to embody and replicate
observed experimental results, but also to explore the effects of the alteration
of different characteristics of the treatment. The tumour characteristics have
a profound effect on the efficacy of treatment, so too does the viral infectiv-
ity. In Fig. 5c we have simulated the tumour cell population profile in time
for a range of viral infectivities, β. Our results suggest that there is a certain
β threshold, above which we can achieve complete tumour eradication. This
reinforces the ideas of Kim et al (2011) that improving viral infectivity would
be the key to achieving complete tumour eradication.
The efficacy of the viral treatment is affected not only by the inherent
characteristics of the virus, but also by the application profile. Experimental
studies can only explore a finite number of strategies. Our model, however, can
be used to simulate any number of application strategies. Fig. 6 demonstrates
some key features of the effects of increasing the viral dose delivered as well
as altering the application profile.
One major concern in viral treatments is toxicity. Tracking the maximum
viral level during the first 100 days of treatment shows an initial decrease as
the application dose increases, independent of the application profile, Fig. 6a.
This likely corresponds to the increasing effectiveness of the dose in decreasing
the tumour population, and thus also limiting the maximum viral population.
For small values of D0 we see that one injection achieves a smaller maximum
virus level compared to spreading the dose over increasing numbers of injec-
tions. The maximum viral population then goes on to climb almost linearly
as D0 is further increased irrespective of the application profile. We interpret
this as the virus being too effective in killing off the tumour cells before they
proliferate, thus also slowing viral replication. By spreading the total viral dose
into multiple injections, the peak viral load is constrained, despite having an
initial higher dose, as seen in the lesser gradients of the multiple injections
application profiles. We can conclude from this that viral replication is not
the driving force behind tumour cell eradication in these scenarios, but rather
the intravenous virus is the major player in the eradication. Naturally many
application profiles can be considered. Given a particular viral treatment, and
the biological constraints such as maximum viral load tolerance, the model
can be utilised to optimise the proposed application profile.
In the absence of negative effects of viral overload it would seem from
Fig. 6b that the best strategy for fast-tumour eradication would be a single,
very high dose injection. Realistically, however, the choice of treatment strat-
egy will depend on interplay between dosage size and eradication half time.
Comparing the high dose single injection to application protocols with ten
days between injections, however, we can see that much lower viral doses D0
are required to reach finite eradication half time. Increasing the days between
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injections can lessen the dose required to reach eradication and this trend
appears almost insensitive to the number of injections. Overall, application
protocols with two injections appear to provide good combinations of lower
doses and reasonably short eradication half times.
In certain cases, complete tumour eradication may not be possible or even
the most desirable outcome. Our analysis shows that limiting and reducing
tumour size and growth is a possibility under the current or slightly modi-
fied treatment regime. Shrinkage and then surgical removal may be a possible
treatment design utilising oncolytic viruses and may be less detrimental than
chemotherapy.
5 Conclusion
The mathematical model of tumour cell-virus interactions derived in this
study, while simple, is a good representation of this biological system. We
have shown that the tumour characteristics of proliferation rate and initial
tumour size are critical factors in the outcome of the interaction between an
oncolytic virus and tumour cells.
In devising strategies for tumour eradication, the modelling confirms that
viral infectivity is a key parameter. For a particular infectivity, however, the ap-
plication profile can be an important determinant of the efficacy and toxicity of
the treatment. Using mathematical modelling, combined with subject-specific
responses, increasingly successful oncolytic viral therapies can be designed.
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